Trial Profile

A Study to Characterize the Safety and Efficacy of Tafamidis Once Daily in the Treatment of Transthyretin Amyloid Cardiomyopathy in Chinese Participants

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tafamidis meglumine (Primary)
Indications Cardiomyopathies; Transthyretin-related hereditary amyloidosis
Focus Adverse reactions
Sponsors Pfizer

Most Recent Events

07 Nov 2023 Status changed from active, no longer recruiting to completed.
14 Dec 2022 Planned End Date changed from 2 Oct 2023 to 16 Oct 2023.
14 Dec 2022 Planned primary completion date changed from 2 Oct 2023 to 16 Oct 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com